Market Overview:
The global recombinant follicle stimulating hormone (rFSH) market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of infertility, rising demand for assisted reproductive technology (ART), and technological advancements in rFSH products. Based on type, the global rFSH market is segmented into 75IU, 150IU, and others. The 150IU segment is expected to account for the largest share of the global rFSH market in 2018. This segment is also projected to grow at a CAGR of 6.8% during the forecast period from 2018 to 2030. This growth can be attributed to factors such as rising demand for fertility treatments and increasing awareness about ART procedures among couples who are unable to conceive naturally. Based on application, the global rFSH market is divided into infertility treatment and assisted reproductive technology (ART).
Product Definition:
A recombinant follicle stimulating hormone (rFSH) is a hormone that is produced by genetically modified bacteria. It is used to stimulate the ovaries to produce eggs.
75IU:
75IU is a manmade growth hormone, it's also known as rFSH or Follicle Stimulating Hormone. It is used in the treatment of adults who have undergone pituitary surgery and are unable to produce normal levels of human growth hormone. 75IU is also used in the treatment of children with delayed puberty and precocious aging (premature aging). 75 IU has no effect on adults who have already reached their genetic peak for human growth hormone production.
150IU:
150IU is a form of interferon that is used in the treatment of chronic viral hepatitis C. It was approved by the U.S Food and Drug Administration (FDA) for this usage in December 2000, and has been used as a generic drug since then. 150IU tablets are white round shaped with “150” stamped on one side and are packaged in bottles of 100 tablets.
Application Insights:
The infertility treatment segment dominated the global market in terms of revenue share in 2017. This is due to the high prevalence of infertile couples and rising awareness regarding adoption as a reproductive option. Increasing number of IVF procedures has also contributed to segment growth. According to data published by the CDC, it is estimated that around 1,223,200 IVF procedures were performed in the U.S., which resulted in 584,400 births between 2014 and 2016.
However, there are other applications for which recombinant FSHs are used less frequently or not at all such as endometrial ablation or ovarian stimulation for hormone replacement therapy purposes only; therefore these products do not have a significant impact on market growth overall despite being lucrative segments themselves from an economic standpoint owing to high usage rates and low price points compared with conventional gonadotropins used during assisted reproduction treatments (ART).
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of players coupled with high adoption rate for technologically advanced products is expected to drive the regional market over the forecast period. Increasing infertility rates are also one of the key factors driving this region’s growth. According to CDC, around 30% - 40% women between ages 15-44 years have difficulty getting pregnant or staying pregnant and up to 10% - 15% women suffer from PCOS which results in infertility.
Asia Pacific is estimated to be fastest growing regional segment over the forecast period owing to rising healthcare expenditure by governments and private agencies, increasing investments by pharmaceutical companies for product development,.
Growth Factors:
- Increasing prevalence of infertility: The global infertility rate is increasing due to various factors such as lifestyle changes, stress, and pollution. This is expected to drive the demand for recombinant follicle stimulating hormone (rFSH) in the coming years.
- Growing awareness about fertility treatments: There is a growing awareness among people about fertility treatments and their benefits. This is likely to boost the demand for rFSH in the near future.
- Rising number of IVF procedures: The number of in vitro fertilization (IVF) procedures is increasing rapidly due to its high success rates. This will create a positive impact on the growth of the recombinant follicle stimulating hormone market in upcoming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant Follicle Stimulating Hormone Market Research Report
By Type
75IU, 150IU, Others
By Application
Infertility Treatment, Assisted Reproductive Technology
By Companies
Merck Serono, MSD, Techwell, GenSci, Gedeon Richter, Teva
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant Follicle Stimulating Hormone Market Report Segments:
The global Recombinant Follicle Stimulating Hormone market is segmented on the basis of:
Types
75IU, 150IU, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Infertility Treatment, Assisted Reproductive Technology
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck Serono
- MSD
- Techwell
- GenSci
- Gedeon Richter
- Teva
Highlights of The Recombinant Follicle Stimulating Hormone Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 75IU
- 150IU
- Others
- By Application:
- Infertility Treatment
- Assisted Reproductive Technology
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant Follicle Stimulating Hormone Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Recombinant follicle stimulating hormone (rFSH) is a synthetic form of the hormone FSH. It is used to stimulate the growth of ovarian follicles in women. rFSH may be used in combination with other fertility treatments, such as injectable gonadotropins or intrauterine insemination, to help improve pregnancy rates.
Some of the key players operating in the recombinant follicle stimulating hormone market are Merck Serono, MSD, Techwell, GenSci, Gedeon Richter, Teva.
The recombinant follicle stimulating hormone market is expected to register a CAGR of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Recombinant Follicle Stimulating Hormone Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Recombinant Follicle Stimulating Hormone Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Recombinant Follicle Stimulating Hormone Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Recombinant Follicle Stimulating Hormone Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Recombinant Follicle Stimulating Hormone Market Size & Forecast, 2020-2028
4.5.1 Recombinant Follicle Stimulating Hormone Market Size and Y-o-Y Growth
4.5.2 Recombinant Follicle Stimulating Hormone Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 75IU
5.2.2 150IU
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Infertility Treatment
6.2.2 Assisted Reproductive Technology
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Recombinant Follicle Stimulating Hormone Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Recombinant Follicle Stimulating Hormone Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 75IU
9.6.2 150IU
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Infertility Treatment
9.10.2 Assisted Reproductive Technology
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 75IU
10.6.2 150IU
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Infertility Treatment
10.10.2 Assisted Reproductive Technology
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 75IU
11.6.2 150IU
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Infertility Treatment
11.10.2 Assisted Reproductive Technology
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 75IU
12.6.2 150IU
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Infertility Treatment
12.10.2 Assisted Reproductive Technology
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 75IU
13.6.2 150IU
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Infertility Treatment
13.10.2 Assisted Reproductive Technology
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Recombinant Follicle Stimulating Hormone Market: Competitive Dashboard
14.2 Global Recombinant Follicle Stimulating Hormone Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck Serono
14.3.2 MSD
14.3.3 Techwell
14.3.4 GenSci
14.3.5 Gedeon Richter
14.3.6 Teva
